ZSAN
Zosano Pharma Corporation [ZSAN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ZSAN Stock Summary
In the News
ZSAN Financial details
Company Rating
-
Market Cap
0
Income
-55.32M
Revenue
659K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
13 May 2022
P/E
-2.08
Forward P/E
-
PEG
-0.01
P/S
-
P/B
1.89
P/C
-
P/FCF
-
Quick Ratio
1.01
Current Ratio
1.04
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.07
EPS next Y
-
EPS next Q
-
EPS this Y
-44.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
51.72%
EPS Q/Q
13255.93%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-62%
ROE
-75%
ROC
-0.8%
Gross Margin
-1%
Oper. Margin
-3788%
Profit Margin
-3836%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.46-0.635
52W High
-
52W Low
-
RSI
19.71
Rel Volume
-
Avg Volume
5.36M
Volume
5.69K
Perf Week
-71.43%
Perf Month
-
Perf Quarter
-
Perf Half Y
-60%
-
-
-
-
Beta
3.28539
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0002
Change
0%
Company Profile
- Volume Average 5.36M
- Employee 40
- CEO Steven Lo
- Headquarters Fremont,CALIFORNIA,US
- IPO Date 2015-01-27
-
Website
https://www.zosanopharma.com 
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
